Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems
- aDivision of Chemistry and Chemical Engineering, 1200 E. California Boulevard, MC 210-41, California Institute of Technology, Pasadena, CA 91125;
- bDepartment of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope, Duarte, CA 91010; and
- cDepartment of Bioengineering, 473 Via Ortega, MC 4201, Stanford University, Stanford, CA 94305
-
Edited* by Mark E. Davis, California Institute of Technology, Pasadena, CA, and approved March 30, 2010 (received for review February 17, 2010)
-
↵1M.C.J. and C.D.S. contributed equally to this work.
Abstract
RNA molecules perform diverse regulatory functions in natural biological systems, and numerous synthetic RNA-based control devices that integrate sensing and gene-regulatory functions have been demonstrated, predominantly in bacteria and yeast. Despite potential advantages of RNA-based genetic control strategies in clinical applications, there has been limited success in extending engineered RNA devices to mammalian gene-expression control and no example of their application to functional response regulation in mammalian systems. Here we describe a synthetic RNA-based regulatory system and its application in advancing cellular therapies by linking rationally designed, drug-responsive, ribozyme-based regulatory devices to growth cytokine targets to control mouse and primary human T-cell proliferation. We further demonstrate the ability of our synthetic controllers to effectively modulate T-cell growth rate in response to drug input in vivo. Our RNA-based regulatory system exhibits unique properties critical for translation to therapeutic applications, including adaptability to diverse ligand inputs and regulatory targets, tunable regulatory stringency, and rapid response to input availability. By providing tight gene-expression control with customizable ligand inputs, RNA-based regulatory systems can greatly improve cellular therapies and advance broad applications in health and medicine.
Footnotes
- 2To whom correspondence should be addressed. E-mail: csmolke{at}stanford.edu.
-
Author contributions: Y.Y.C., M.C.J., and C.D.S. designed research; Y.Y.C. performed research; Y.Y.C., M.C.J., and C.D.S. analyzed data; and Y.Y.C., M.C.J., and C.D.S. wrote the paper.
-
Conflict of interest statement: We declare competing financial interests in the form of a pending patent application whose value may be affected by the publication of this manuscript.
-
*This Direct Submission article had a prearranged editor.
-
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1001721107/-/DCSupplemental.











